Lista de obras - Luis León - Dominio Público Uruguay

A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Stu

artículo científico publicado en 2016

A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer ⬇️

artículo científico publicado el 1 de octubre de 2012

Association of Salivary Human Papillomavirus Infection and Oral and Oropharyngeal Cancer: A Meta-Analysis

artículo científico publicado en 2020

Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02).

artículo científico publicado en 2007

CT perfusion in oncologic imaging: a useful tool?

artículo científico publicado en 2013

Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor ⬇️

artículo científico publicado el 12 de febrero de 2013

Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome.

artículo científico publicado en 2017

Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor

artículo científico publicado en 2015

First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

artículo científico publicado en 2012

Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer.

artículo científico publicado en 2001

Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group

artículo científico publicado en 2003

Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients

scientific article published on 01 July 2020

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

artículo científico publicado en 2016

Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients

artículo científico publicado en 2017

Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.

artículo científico

Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study ⬇️

artículo científico publicado el 16 de septiembre de 2010

Molecular basis of hypertension side effects induced by sunitinib

artículo científico publicado en 2011

New advances in genitourinary cancer: evidence gathered in 2014.

artículo científico

Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.

artículo científico publicado en 2017

PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis

artículo científico publicado en 2020

Poxviral-based prostate-specific antigen vaccine in prostate cancer.

artículo científico publicado en 2010

PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system.

artículo científico publicado en 2017

Quality of life and supportive care for patients with metastatic renal cell carcinoma.

artículo científico publicado en 2012

Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.

artículo científico publicado en 2015

Radium-223 international early access program: results from the Spanish subset.

artículo científico publicado en 2017

Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.

artículo científico

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

artículo científico

Sorafenib in renal cell carcinoma

artículo científico publicado en 2011

Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma ⬇️

artículo científico publicado el 7 de febrero de 2012

Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases

artículo científico publicado en 2011

The immunohistochemical expression of cyclin B1 is associated with higher SUV in 18F-FDG-PET in non-small cell lung cancer patients. Initial results

artículo científico publicado en 2009

The immunohistochemical expression of cyclooxygenase 2 is inversely associated with (18)F-FDG-PET SUV values in non-small-cell lung cancers. Initial results

artículo científico publicado en 2009

The maximum standardized uptake value (18)F-FDG PET is independent of the immunohistochemical expression of platelet derived endothelial growth factor in patients with non-small cell lung cancer

artículo científico publicado en 2009

Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors.

artículo científico publicado en 2015

Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors

artículo científico publicado en 2007

[Quality of life after biochemical recurrence in patients with prostate cancer. How and how long do patients live after biochemical recurrence?]

artículo científico publicado en 2012

[Use of M-VAC in the adjuvant treatment of sarcomatoid carcinoma of the bladder]

scientific article published on 01 April 2009

Lista de obras de Luis León

A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Stu

A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer ⬇️

Association of Salivary Human Papillomavirus Infection and Oral and Oropharyngeal Cancer: A Meta-Analysis

Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02).

CT perfusion in oncologic imaging: a useful tool?

Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor ⬇️

Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome.

Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor

First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer.

Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group

Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients

Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.

Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study ⬇️

Molecular basis of hypertension side effects induced by sunitinib

New advances in genitourinary cancer: evidence gathered in 2014.

Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.

PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis

Poxviral-based prostate-specific antigen vaccine in prostate cancer.

PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system.

Quality of life and supportive care for patients with metastatic renal cell carcinoma.

Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.

Radium-223 international early access program: results from the Spanish subset.

Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

Sorafenib in renal cell carcinoma

Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma ⬇️

Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases

The immunohistochemical expression of cyclin B1 is associated with higher SUV in 18F-FDG-PET in non-small cell lung cancer patients. Initial results

The immunohistochemical expression of cyclooxygenase 2 is inversely associated with (18)F-FDG-PET SUV values in non-small-cell lung cancers. Initial results

The maximum standardized uptake value (18)F-FDG PET is independent of the immunohistochemical expression of platelet derived endothelial growth factor in patients with non-small cell lung cancer

Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors.

Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors

[Quality of life after biochemical recurrence in patients with prostate cancer. How and how long do patients live after biochemical recurrence?]

[Use of M-VAC in the adjuvant treatment of sarcomatoid carcinoma of the bladder]